RT Book, Section
A1 La-Beck, Ninh M.
A1 Selby, Christopher
A2 Chisholm-Burns, Marie A.
A2 Schwinghammer, Terry L.
A2 Malone, Patrick M.
A2 Kolesar, Jill M.
A2 Bookstaver, P. Brandon
A2 Lee, Kelly C.
SR Print(0)
ID 1187022239
T1 Lung Cancer
T2 Pharmacotherapy Principles & Practice, 6e
YR 2022
FD 2022
PB McGraw-Hill Education
PP New York, NY
SN 9781260460278
LK ppp.mhmedical.com/content.aspx?aid=1187022239
RD 2024/09/14
AB LEARNING  OBJECTIVESUpon  completion  of  the  chapter,  the  reader  will  be  able  to:Identify  major  risk  factors  for  the  development  of  lung  cancer.Explain  the  pathologic  progression  of  lung  cancer  and  its  relationship  with  signs  and  symptoms  of  the  disease.Make  appropriate  recommendations  for  screening  and  preventive  measures  in  high-risk  patients.Understand  staging  of  lung  cancer  patients  and  how  it  influences  treatment  decisions.Explain  how  histology,  biomarkers,  and  genetic  mutational  testing  are  used  to  select  therapy.List  the  rationale,  advantages,  and  disadvantages  for  neoadjuvant  and  adjuvant  chemotherapy  in  non–small  cell  lung  cancer  (NSCLC).Identify  the  treatment  of  choice  and  treatment  goals  for  limited  and  extensive  small-cell  lung  carcinoma.Identify  the  treatment  of  choice  and  treatment  goals  for  local,  locally  advanced,  and  advanced  non–small  cell  lung  carcinoma.